Rathbones Group’s Xenon Pharmaceuticals XENE Stock Holding History

Rathbones Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.4M	Sell	23,166 -500	-2%	-$27.8K	0.01%	336
2026 Q1	$1.38M	Hold	23,666	–	–	0.01%	328
2025 Q4	$1.06M	Hold	23,666	–	–	﹤0.01%	360
2025 Q3	$950K	Hold	23,666	–	–	﹤0.01%	354
2025 Q2	$741K	Hold	23,666	–	–	﹤0.01%	379
2025 Q1	$794K	Hold	23,666	–	–	﹤0.01%	350
2024 Q4	$928K	Hold	23,666	–	–	﹤0.01%	342
2024 Q3	$932K	Hold	23,666	–	–	﹤0.01%	339
2024 Q2	$923K	Hold	23,666	–	–	0.01%	335
2024 Q1	$1.02M	Hold	23,666	–	–	0.01%	324
2023 Q4	$1.09M	Hold	23,666	–	–	0.01%	300
2023 Q3	$808K	Buy	+23,666	New	+$885K	0.01%	337

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Rathbones Group's XENE Position: Q2 2026 in Review

Rathbones Group reduced its Xenon Pharmaceuticals (XENE) stake by 2.1% in Q2 2026, selling an estimated $27.8K and leaving 23,166 shares worth $1.4M. The position accounts for 0.01% of the portfolio, ranked #336.

Rathbones Group first reported a position in XENE in Q3 2023 and has held it in 12 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Rathbones Group held 23,166 shares of Xenon Pharmaceuticals worth $1.4M as of Q2 2026.
Rathbones Group sold 500 Xenon Pharmaceuticals shares in Q2 2026, an estimated $27.8K.
Xenon Pharmaceuticals made up 0.01% of Rathbones Group's portfolio in Q2 2026, its #336 holding.
Rathbones Group first reported a position in Xenon Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.